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Introduction
Sickle cell disease (SCD) is caused by a mutation in the
hemoglobin β chain, resulting in the production of an abnor-
mal hemoglobin (HbS) in the erythrocyte. Under conditions
of low oxygenation, HbS polymerizes leading the erythrocyte
to adopt a sickle-shaped morphology. SCD is characterized
by complex pathophysiological mechanisms that involve
intravascular hemolysis and recurrent vaso-occlusion, in asso-
ciation with chronic vascular inflammation and endothelial
activation,1,2 leading to numerous clinical complications that
include painful vaso-occlusive episodes, auto-infarction of the
spleen, acute chest syndrome, stroke, pulmonary hyperten-
sion, renal damage and a shortened lifespan.3
Angiogenesis is the formation of new capillaries from pre-
existing vessels and is essential for processes of development,
reproduction and repair.4 Alterations in angiogenesis have
been associated with a number of pathological conditions,
particularly in inflammatory diseases, and angiogenesis,
chronic inflammation and cellular responses to changes in
oxygen tension appear to be co-dependent.5-7 The angiogenic
process involves interactions of several cell types and mecha-
nisms to establish a precise microenvironment appropriate for
capillary formation,8 where endothelial cell (EC) proliferation
and invasion occur in response to angiogenic mediators, fol-
lowed by cell anastomosis to form lumen-containing capillar-
ies.9,10
Although homozygous sickle cell anemia (HbSS; SCA) is
often associated with a more severe phenotype, patients with
HbSC disease (in which red cells produce both HbS and HbC)
can have a similar or higher incidence of retinopathy and
osteonecrosis, among other manifestations.11 The levels of a
number of angiogenic mediators have been reported to be
elevated in SCD, including vascular endothelial growth factor
(VEGF), placental growth factor (PlGF), angiopoietin-1
(Ang1), angiopoietin-2 (Ang2) and erythropoietin (EPO).12-16 In
addition, despite the heterogeneity of the SCD phenotype,
several clinical manifestations associated with SCD, including
proliferative retinopathy, pulmonary hypertension, leg ulcers
and moyamoya syndrome, suggest an involvement of patho-
logical angiogenic processes.17-24 Although these observations
indicate an angiogenic imbalance in SCD, the existence of
pro-angiogenic mechanisms in SCD, and their consequences,
remain unclear.
Hydroxyurea (or hydroxycarbamide) is currently the only
drug approved by the Food and Drug Administration for use
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As hypoxia-induced inflammatory angiogenesis may contribute to the manifestations of sickle cell disease, we
compared the angiogenic molecular profiles of plasma from sickle cell disease individuals and correlated these with
in vitro endothelial cell-mediated angiogenesis-stimulating activity and in vivo neovascularization. Bioplex demon-
strated that plasma from patients with steady-state sickle cell anemia contained elevated concentrations of pro-
angiogenic factors (angiopoietin-1, basic fibroblast growth factor, vascular endothelial growth factor, vascular
endothelial growth factor-D and placental growth factor) and displayed potent pro-angiogenic activity, significant-
ly increasing endothelial cell proliferation, migration and capillary-like structure formation. In vivo neovasculariza-
tion of Matrigel plugs was significantly greater in sickle cell disease mice than in non-sickle cell disease mice, con-
sistent with an up-regulation of angiogenesis in the disease. In plasma from patients with hemoglobin SC disease
without proliferative retinopathy, anti-angiogenic endostatin and thrombospondin-2 were significantly elevated.
In contrast, plasma from hemoglobin SC individuals with proliferative retinopathy had a pro-angiogenic profile
and more significant effects on endothelial cell proliferation and capillary formation than plasma from patients
without retinopathy. Hydroxyurea therapy was associated with significant reductions in plasma angiogenic factors
and inhibition of endothelial cell-mediated angiogenic mechanisms and neovascularization. Thus, individuals with
sickle cell anemia or hemoglobin SC disease with retinopathy present a highly angiogenic circulating milieu, capa-
ble of stimulating key endothelial cell-mediated angiogenic mechanisms. Combination anti-angiogenic therapy to
prevent the progression of unregulated neovascularization and associated manifestations in sickle cell disease, such
as pulmonary hypertension, may be indicated; furthermore, the benefits and drawbacks of the potent anti-angio-
genic effects of hydroxyurea should be clarified. 
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ABSTRACT
as a therapy in SCD.25 Hydroxyurea is a cytostatic drug
that inhibits ribonucleotide reductase, arresting cell divi-
sion in the S-phase; additionally, data suggest that hydrox-
yurea can generate nitric oxide following administration.26
We recently reported that hydroxyurea exerts anti-angio-
genic effects in VEGF-dependent EC angiogenic in vitro
assays and inhibits VEGF-dependent neovascularization in
Matrigel implants in C57BL/6 mice.27 This anti-angiogenic
activity appears to be mediated by the down-regulation of
endothelial hypoxia-inducible factor-1α (HIF-1α) expres-
sion, and consequent modulation of miRNA 221 expres-
sion, leading to the inhibition of EC proliferation and inva-
sion/migration.27
To lend further support to the hypothesis of an unbal-
anced angiogenic state in SCD, we investigated the in vitro
effects of plasma from patients with SCD on key steps of
EC angiogenic behavior, namely, proliferative capability,
invasive capacity and the formation of capillary-like EC
structures. The plasma contents of angiogenic factors
were associated with these data, as was the incidence of
proliferative retinopathy in HbSC patients, a clinical man-
ifestation thought to reflect augmented angiogenesis.28
The angiogenic activity of plasma from patients on
hydroxyurea therapy was also examined. Finally, to con-
firm that SCD pathophysiology is associated with exacer-
bated angiogenesis, in vivo neovascularization was exam-
ined in a SCD mouse model, compared with non-SCD
mice, utilizing a Matrigel plug angiogenesis assay. 
Methods
Patients
Patients with HbSS or HbSC disease (collectively termed SCD)
were recruited, during steady-state, at the Hematology Center,
UNICAMP (Table 1). Details on the diagnosis of HbSS/HbSC, our
definition of steady-state and criteria for commencing hydroxy -
urea therapy (15–30 mg hydroxyurea/kg/day) are given in the
Online Supplementary Information. All patients had undergone oph-
thalmoscopy and fluorescein angiography for detection of prolif-
erative retinopathy. A total of 29 HbSS patients, who did not have
proliferative retinopathy, were recruited into the study. A total of
33 HbSC patients were recruited, of whom 16 did not have prolif-
erative retinopathy (SC group) and 17 did (SCR group). One HbSC
patient had been prescribed hydroxyurea following an ischemic
stroke. Homozygous hemoglobin A (HbAA) healthy controls
were age- and gender-matched, where possible. Informed written
consent was obtained from all participants and the study was
approved by the UNICAMP Ethics Committee, in accordance
with national guidelines. 
Bioplex assay
The Fluorokine®MAP, Human Angiogenesis Custom Premix Kit
A (R&D Systems, Minneapolis, USA) was used to quantify Ang1,
basic fibroblast growth factor (bFGF), PlGF, platelet-derived
growth factor (PDGF)-AA, PDGF-BB, VEGF, VEGF-D, endostatin
and thrombospondin-2 (TSP-2) in plasma, according to the manu-
facturer’s instructions. The preparation of the plasma for the assay
is described in the Online Supplementary Information. 
In vitro culture of human umbilical vein endothelial
cells
Human umbilical vein endothelial cells (HUVEC), obtained
from the Global Bioresource Center (ATCC) were cultured, as
described elsewhere.27 Before all assays, cells (fourth to sixth pas-
sage) were incubated in low-serum-containing media (2% fetal
bovine serum). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide) assays were employed to verify HUVEC via-
bility.27
Bromodeoxyuridine proliferation assay
HUVEC (1×104 cells/mL) were cultured in the absence or pres-
ence of 10% (v/v) plasma for 24 h, before quantifying cell prolifer-
ation by enzyme-linked immunosorbent assay using the Cell
Proliferation bromodeoxyuridine (BrdU) kit (Roche, Penzberg,
Germany), according to the manufacturer's instructions. 
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Table 1. Demographic, clinical and hematologic details of the patients participating in the study.
SS SSHU SC SCR SCRHU
Male/female (n.) 4/13 9/3 4/12 9/7 0/1
Age (years) 38 (38; 21, 51) 39 (39; 23, 54) 37  (37;16, 52) 46  (47; 33, 59) 67
Red blood cell count (1012/L) 2.74 2.50 4.42 4.42 2.43
(2.72; 1.74, 3.97) (2.48; 1.89, 3.63) (4.50; 2.74, 5.56) (4.47; 3.50, 5.53)
Hematocrit (%) 24.5 26.5 33.5 34.8  26.8
(24.1; 16.9, 32.9) (26.4; 20.8, 37.4) (33.2; 8.1, 14.3) (35.0; 28.8, 40.4)
Hemoglobin (g/dL) 8.1 8.9  11.5   11.9 9.6
(8.1; 5.9, 11.0) (8.3; 6.8, 12,9) (11.1; 8.1, 14.3) (12.0; 10.0, 14.1)
Mean corpuscular volume (fL) 90.5 107.3 76.7 79.1 110.1
(90.5; 75.4, 103.6) (103.5; 84.9, 137.6) (77.1; 56.3, 87.9) (78.9; 71.1, 87.3)
Reticulocytes (x109/L) 422 272  187.2  377.5 94.1
(355; 172, 803) (272; 151, 412) (185; 73, 316) (218; 81, 378)
White blood cells (x109/L) 10.5 7.7  8.0  13.4 4.4
(10.6; 6.3, 13.8) (7.2; 4.0, 12.6) (7.7; 4.1, 15.3) (8.2; 3.54, 13.4)
HbF (%) 8.9 14.8 2.1  0.95 4.7
(7.0; 2.1, 25.9) (14.2; 3.8, 25.1) (1.15; 0.3, 8.0) (0.7; 0.2, 2.6)
Platelets (x109/L) 465  365  289   303 231
(422; 111, 1029) (364; 156, 1052) (268; 70, 549) (250; 89, 696)
SS: steady-state SCA patients; HU: hydroxyurea therapy (20-30 mg/kg/day for at least 12 months); SC: steady-state HbSC patients without retinopathy; SCR: steady-state HbSC
patients with proliferative retinopathy.  HbF: fetal hemoglobin. Data (except male/female value) are mean (median; minimim, maximum) values.
Endothelial cell invasion assay
HUVEC migration (during 22 h) in the absence/presence of 10%
(v/v) plasma was quantified using a double-chamber assay (BD
BiocoatTM MatrigelTM Invasion Chamber, BD-Biosciences, Franklin
Lakes, USA), as described elsewhere.27 Results represent the ratio
of invading cells in plasma-treated cultures compared to control
cultures for the same initial amount of cells seeded.
Capillary-formation assay 
HUVEC (5×104 cells/mL) were cultured on growth factor-
reduced Matrigel (BD-Biosciences)-coated plates for 17 h, in medi-
um containing 10% plasma or Ham F12-K medium alone (con-
trol), as previously described.29 A semi-quantitative measurement
of cord formation in the entire Matrigel culture was performed
and expressed as a tube-formation index.29
Animals
Five-month old C57BL/6, chimeric SCD mice and chimeric non-
SCD mice were employed in the study. For details regarding ani-
mals, their maintenance and diet, refer to the Online Supplementary
Information. Animal procedures were carried out in accordance
with the National Institutes of Health revised guide for the care
and use of laboratory animals and current Brazilian laws. This
study was approved by the Commission for Ethics in Animal
Experimentation, UNICAMP (Protocol 3024-1, 2013). 
In vivo Matrigel plug neovascularization assay
Matrigel was prepared with heparin in the absence or presence
of recombinant VEGF (R&D Systems; 100 ng/mL, as previously
standardized30) and 100 μM hydroxyurea before subcutaneous
inoculation into mice. Animals were euthanized after 7 days, and
the Matrigel plugs were removed, weighed, photographed and
hemoglobin content quantified, as previously described.30
Statistical analysis
The statistical analyses are described in the Online Supplementary
Information.
Results
Circulating pro-angiogenic factor levels are significantly
increased in steady-state sickle cell anemia 
Plasma was collected from control individuals (AA) and
F.C.M. Lopez et al.
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Figure 1. Pro-angiogenic factor levels in SCA. Levels of (A) Ang1, (B) bFGF, (C) VEGF,
(D) VEGF-D, (E) PlGF, (F) PDGF-AA and (G) PDGF-BB, quantified in the plasma of
healthy control individuals (AA), HbSS patients not treated with hydroxyurea (SS) and
HbSS patients treated with hydroxyurea (SSHU; 15-30 mg/kg/day) using Bioplex tech-
nology. Bars represent means ± SD.
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steady-state SCA individuals not on hydroxyurea therapy
(SS). A Bioplex assay demonstrated that the levels of the
pro-angiogenic factors Ang1, bFGF, VEGF, VEGF-D and
PlGF were all significantly elevated (P<0.05), in the plasma
of steady state SCA patients (not on hydroxyurea), com-
pared to the levels in healthy control individuals (Figure 1).
Levels of PDGF-AA and -BB were not significantly altered
in SCA patients, compared to control individuals.
Hydroxyurea therapy is associated with a reduction in
circulating pro-angiogenic factors in sickle cell anemia 
When levels of pro-angiogenic factors were compared in
SCA patients on hydroxyurea (SSHU) with those not on
hydroxyurea (SS) and control individuals (AA) (Figure 1),
both bFGF and VEGF, which were significantly augment-
ed in SS individuals, were unchanged compared to con-
trols. Surprisingly, Ang1, VEGF-D, PDGF-AA and PDGF-
BB were even lower in SSHU patients than in control (AA)
individuals (P<0.05); PlGF was significantly increased in
SSHU patients compared to AA individuals (P<0.05), but
mean levels were lower than those of SS individuals
(P<0.01). 
Circulating pro-angiogenic factor levels in steady-state
HbSC disease
In a second group of analyses, pro-angiogenic factors
were measured in the plasma of control (AA) individuals,
steady-state HbSC individuals without retinopathy (SC),
steady-state HbSC individuals with proliferative retinopa-
thy (SCR) and in one SCR patient on hydroxyurea therapy
(SCRHU) (Figure 2). PlGF, alone, was found to be elevated
in SC plasma (P<0.001), compared to the level in control
individuals. Interestingly, PDGF-BB was significantly
decreased (P<0.05) in the SC group compared to AA con-
trols. In those SC patients with retinopathy (SCR), a very
different profile of pro-angiogenic factor expression was
observed. Levels of Ang1, VEGF, VEGF-D and PlGF were
all significantly elevated (P<0.05), compared to those in
AA control subjects (Figure 2), while levels of PDGF-BB
were similar to those of AA controls. No significant differ-
ence was observed in PDGF-AA levels, either relative to
controls or to SC individuals. The SCRHU patient had
increased Ang1 and PlGF levels and decreased bFGF, VEGF,
VEGF-D, PDGF-AA and PDGF-BB levels, when compared
to the control (AA) group. 
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Figure 2. Pro-angiogenic factor levels in HbSC disease. (A) Ang1, (B) bFGF, (C) VEGF, (D)
VEGF-D, (E) PlGF, (F) PDGF-AA and (G) PDGF-BB, quantified in the plasma of healthy
control individuals (AA), HbSC patients without proliferative retinopathy (PR) and not
treated with hydroxyurea (SC), HbSC patients with PR and not treated with hydroxyurea
(SCR) and a HbSC patient with PR treated with hydroxyurea (SCRHU) using Bioplex
technology. Bars represent means±SD.
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Circulating anti-angiogenic factors are altered in HbSC
disease and in those patients with sickle cell anemia
on hydroxyurea therapy
Anti-angiogenic factors were assayed in the same
groups of patients. Endostatin and TSP-2 levels were no
different in SCA patients (SS) from those in healthy indi-
viduals (AA) (Figure 3A,B). Importantly, endostatin and
TSP-2 levels were significantly higher (P<0.05) in HbSC
(SC) patients than in healthy controls (Figure 3C,D), but
were not significantly different in those SC patients with
proliferative retinopathy (SCR).
Hydroxyurea therapy was associated with significant
increases in both endostatin and TSP-2 in SCA (Figure
3A,B; P<0.01), while a relative elevation in both these fac-
tors was observed in the SCR patient on hydroxyurea
(Figure 3C,D).
Endothelial cell proliferation and invasion are
enhanced in the presence of sickle cell disease 
plasma and inhibited by plasma from sickle cell 
disease patients treated with hydroxyurea 
The effects of plasma from these individuals on key
steps of the angiogenic process was studied, in vitro, using
cultured HUVEC. Initially, possible cytotoxic effects of
plasma (10-20% v/v) on HUVEC viability were assessed
using an MTT assay (data not shown). Plasma had insignif-
icant cytotoxicity for HUVEC, and a plasma concentration
of 10% (v/v) was used for subsequent HUVEC assays. 
EC proliferation and migration/invasion are crucial for
new vessel formation. Incubation of HUVEC with 10%
plasma from SCA patients not treated with hydroxyurea
(SS) for 24 h significantly increased cell proliferation
(P<0.001), as determined by the BrdU proliferation assay.
In contrast, plasma from HbSS patients being treated with
hydroxyurea (SSHU) reduced cell proliferation relative to
that of controls (P<0.001). Interestingly, 10% plasma from
HbSC patients with or without proliferative retinopathy
(SCR and SC, respectively) did not modify cell prolifera-
tion when compared to AA plasma, but plasma from an
HbSC patient on hydroxyurea (SCRHU) reduced prolifer-
ation by about 13% (Figure 4A). 
A double-chamber assay demonstrated a significantly
increased cell invasion capacity for HUVEC when incubat-
ed with plasma from HbSS patients not treated with
hydroxyurea  (SS; P<0.01) (Figure 4B). In contrast, plasma
from SS patients on hydroxyurea (SSHU) significantly
decreased cell invasion (P<0.01). Plasma from HbSC
patients without proliferative retinopathy (SC) increased
cell invasion, although, plasma from HbSC patients with
proliferative retinopathy (SCR) increased cell invasion sig-
nificantly more (P<0.05). Furthermore, plasma from an
HbSC patient with proliferative retinopathy on hydroxy -
urea (SCRHU) decreased cell invasion by about 46%
(Figure 4B).
Plasma from sickle cell disease patients is highly 
pro-angiogenic, augmenting endothelial capillary-like
structure formation, in vitro
We looked at the effects of plasma from healthy individ-
uals and individuals with SCD on the ability of HUVEC to
form capillary-like structures on Matrigel, as the prolifera-
tion and rearrangement of EC to assemble tube-like for-
mations constitutes a major step in angiogenesis. In keep-
ing with reports suggesting that human plasma, in the
F.C.M. Lopez et al.
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Figure 3. Anti-angiogenic factor
levels in SCA and HbSC disease.
(A) Endostatin and (B) throm-
bospondin-2 were quantified in
the plasma of healthy control
individuals (AA), HbSS patients
not treated with hydroxyurea
(SS) and HbSS patients treated
with hydroxy urea (SSHU). (C)
Endostatin and (D) throm-
bospondin-2  were quantified in
the plasma of HbSC patients
without proliferative retinopathy
(PR) and not treated with
hydroxyurea (SC), HbSC patients
with PR and not treated with
hydroxyurea (SCR) and a HbSC
patient with PR treated with
hydroxyurea (SCRHU) using
Bioplex technology. Bars repre-
sent means±SD.
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absence of diseases, is generally slightly anti-angiogenic,
plasma from healthy individuals (AA; 10%) marginally
decreased the formation of capillary-like structures by
HUVEC (P>0.05) compared to control cells (HUVEC in
medium alone) after 17 h of incubation (Figure 5A). In
addition, the morphology of the endothelial tubes was
similar in the two groups (Figure 5B, C). 
In contrast, capillary-like-structure formation increased
significantly in the presence of plasma from SCA and
HbSC patients, independently of the presence of prolifer-
ative retinopathy (P<0.05), and SCR plasma induced sig-
nificantly more capillary formation than did SC plasma
(Figure 5A; P<0.05). HUVEC cultured in the presence of
SCD plasma formed branching and thick anastomosing
capillaries on Matrigel (Figure 5D, F and G). Notably,
HUVEC cultures incubated with plasma from patients
treated with hydroxyurea (SSHU and SCRHU) showed
considerably less angiogenic activity compared to control
cultures, where tube formation indices decreased signifi-
cantly in the presence of SSHU plasma (P<0.01) (Figure
5A). Furthermore, capillaries formed in the presence of
these samples of plasma displayed decreased branching
and occasional single EC could be observed in cultures
(Figure 5E and H).
Pro-angiogenic factor concentration correlates with 
the angiogenic activity of sickle cell disease plasma 
The angiogenic factor concentrations of each of the plas-
ma samples from HbSS and HbSC individuals were corre-
lated with the ability of each respective plasma sample to
induce EC proliferation, invasion and capillary formation
in HUVEC assays. Table 2 demonstrates that the pro-
angiogenic factor content of each plasma sample correlat-
ed significantly with the capillary-formation and invasion-
inducing activities of the HbSS plasma samples. Plasma
Ang1, VEGF, VEGF-D and PDGF-AA concentrations corre-
lated positively and significantly with the ability of the
respective plasma sample to induce cell invasion and cap-
illary formation, while plasma bFGF and PlGF levels corre-
lated only with the ability of the sample to induce capil-
lary formation. For HbSC plasma, VEGF-D content corre-
lated significantly with HUVEC capillary formation and
migration, while Ang1, VEGF and VEGF-D concentrations
correlated with EC capillary formation, proliferation and
invasion when all HbSS/SC plasma samples were ana-
lyzed together. Levels of anti-angiogenic factors (endo-
statin and TSP-2) did not correlate significantly with the
angiogenic activities of any of the SCD plasma samples
(Table 2).
In vivo neovascularization is increased in sickle cell
disease mice 
To examine whether neovascularization, and therefore
angiogenesis, is altered in SCD in vivo, wild-type C57BL/6
control mice and chimeric SCD mice were injected subcu-
taneously with Matrigel plugs to observe the formation of
new blood vessels over a 7-day period. Matrigel plugs
were supplemented, or not, with recombinant VEGF
and/or 100 μM hydroxyurea. At 7 days, the Matrigel plugs
of C57BL/6 control mice that were not supplemented with
VEGF had low hemoglobin contents and, therefore, low-
level vascularization (Figure 6). In contrast, the basal neo-
vascularization (VEGF-) observed in the Matrigel plugs of
SCD mice was significantly higher than that of C57BL/6
control mice (P<0.05; Figure 6A), in which levels of vascu-
larization approached those of a positive control group in
which the Matrigel was supplemented with VEGF
(VEGF+). Increased vascularization can be visualized as
the red color distributed in the whole plug (Figure 6B).
Matrigel implants in SCD mice treated with both VEGF
and 100 μM hydroxyurea (VEGF+HU) demonstrated a
strong inhibition of vascular development (P<0.05). To
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Figure 4. Effects of SCA and SCD plasma samples on endothelial cell proliferation and invasive capacity. HUVEC were incubated in the pres-
ence or absence of 10% plasma from healthy control individuals (AA), HbSS patients not treated with hydroxyurea (SS), HbSS patients treated
with hydroxyurea (SSHU), HbSC patients without proliferative retinopathy (SC), HbSC patients with proliferative retinopathy (SCR) and an HbSC
patient with proliferative retinopathy and treated with hydroxyurea (SCRHU) (17h, 37°C). (A) Cell proliferation was evaluated by the BrdU
assay. Bars represent the percentage of proliferating cells, in comparison with control cells (culture medium only). (B) Endothelial cell invasive
capacity was evaluated using the double-chamber assay. Bars represent the percentage of invading cells relative to the initial amount of cells
cultured. Results are expressed as percentage of control cells (cultured in the absence of plasma). Assays were performed in triplicate.
Statistical differences between groups were evaluated by one-way analysis of variance (ANOVA test) (mean ± SD; n=5/SCRHU=1; *P<0.05,
**P<0.01, ***P<0.001 vs. AA; ###P<0.001 vs. SS; P<0.05 vs. SC).
BA
rule out any transplant-associated effect on neovascular-
ization in chimeric SCD mice, we carried out similar
Matrigel plug assays on chimeric non-SCD control mice
(irradiated C57BL/6 mice that received C57BL/6 bone
marrow) and found that both VEGF-stimulated and
unstimulated vascularization of plugs was similar to that
of C57BL/6 control mice (n=7; P>0.05, data not shown),
indicating that the transplantation process, per se, has no
significant effect upon neovascularization.
Discussion
While evidence supports the existence of an elevated
production of pro-angiogenic factors in SCD,12-15,31,32 few
studies are available to establish a clear link between
angiogenic factor production and pathological neovascu-
larization in this disease. High levels of stromal-derived
factor-1, augmented PlGF and discretely elevated PDGF-
BB have been associated with pulmonary hypertension or
Figure 5. Effects of SCA and SCD plasma samples on endothelial capillary-like structure formation. (A) Semiquantification of tube-formation
index in HUVEC cultures after incubation or not with 10% plasma from healthy control individuals (AA); HbSS patients not treated with hydrox-
yurea (SS); HbSS patients treated with hydroxyurea (SSHU); HbSC patients without proliferative retinopathy (SC); HbSC patients with prolifera-
tive retinopathy (SCR); and a HbSC patient with proliferative retinopathy and treated with hydroxyurea (SCRHU) (17h, 37°C). Bars correspond
to the tube formation index of HUVEC, compared to that of control cells (Control), incubated on Matrigel without plasma. Statistical differences
between groups were evaluated by one-way analysis of variance (ANOVA test) (mean ± SD; n=5/SCRHU=1; *P<0.05, ***P<0.001 vs. AA;
###P<0.001 vs. SS; P<0.05 vs. SC). Photomicrographs (B-H) are representative images of capillary-like structure assembly of HUVEC cultures
on Matrigel. Each culture was established in triplicate and visualized under a phase-contrast inverted microscope (50× magnification) (Zeiss
Axiovert S100 - Moticam 2500).
Table 2. Correlations between levels of angiogenic factors and plasma angiogenic activity.
Ang1 bFGF VEGF VEGF-D PlGF PDGF-AA PDGF-BB Endostatin TSP-2
SS (N≥8) Capillary rs=0.964 rs=0.810 rs=0.881 rs=0.898 rs=0.810 rs=0.762 rs=0.201 rs= 0.095 rs=-0.107
formation P=0.003 P=0.02 P=0.007 P=0.005 P=0.02 P=0.04 P=0.44 P= 0.84 P= 0.84
Proliferation rs=0.571 rs=0.333 rs=0.571 rs=0.575 rs=0.048 rs=0.310 rs=0.119 rs= -0.357 rs=-0.642
P=0.20 P=0.423 P=0.15 P=0.14 P=0.93 P=0.46 P=0.79 P= 0.39 P= 0.39
Invasion rs=0.821 rs=0.452 rs=0.905 rs=0.707 rs=0.548 rs=0.667 rs=0.548 rs= -0.405 rs=-0.107
P=0.03 P=0.27 P=0.004 P=0.06 P=0.17 P=0.08 P=0.17 P= 0.33 P= 0.84
SC (N≥9) Capillary rs=0.383 rs=0.109 rs=0.250 rs=0.767 rs=0.006 rs=-0.018 rs=0.017 rs= -0.346 rs=-0.350
formation P=0.31 P=0.75 P=0.52 P=0.02 P=0.99 P=0.97 P=0.98 P= 0.34 P= 0.36
Proliferation rs=0.167 rs=0.278 rs=0.333 rs=0.887 rs=0.334 rs=0.030 rs=0.150 rs= -0.191 rs=-0.400
P=0.68 P=0.41 P=0.39 P=0.003 P=0.34 P=0.94 P=0.71 P= 0.56 P= 0.29
Invasion rs=0.217 rs=0.400 rs=0.417 rs=0.467 rs=0.527 rs=0.539 rs=-0.067 rs= 0.063 rs=-0.133
P=0.58 P=0.23 P=0.27 P=0.21 P=0.12 P=0.11 P=0.88 P= 0.86 P= 0.74
SS/SC (N≥17) Capillary rs=0.700 rs=0.469 rs=0.657 rs=0.889 rs=0.490 rs=0.348 rs=0.201 rs= -0.233 rs=-0.212
formation P=0.003 P=0.04 P=0.005 P<0.0001 P=0.04 P=0.16 P=0.44 P= 0.34 P= 0.43
Proliferation rs=0.818 rs=0.421 rs=0.576 rs=0.881 rs=0.461 rs=0.286 rs=0.248 rs= -0.252 rs=-0.391
P=0.0002 P=0.07 P=0.02 P<0.0001 P=0.05 P=0.25 P=0.34 P= 0.30 P= 0.14
Invasion rs=0.594 rs=0.379 rs=0.657 rs=0.640 rs=0.474 rs=0.434 rs=0.083 rs= -0.283 rs=-0.006
P=0.02 P=0.11 P=0.005 P=0.007 P=0.04 P=0.11 P=0.75 P= 0.24 P= 0.99
SS: HbSS group (patients on and off hydroxyurea); SC: HbSC group (patients on and off hydroxyurea); Ang1: angiopoietin-1; bFGF: basic fibroblast growth factor; VEGF: vascular endothelial growth
factor; PlGF: placental growth factor; PDGF: platelet-derived growth factor; TSP-2: thrombospondin-2. Spearman correlations were calculated between plasma angiogenic factors and the angiogenic activ-
ity of the plasma sample in endothelial angiogenesis assays. Statistically significant results are shown in bold.
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high tricuspid regurgitation velocity in SCD,13,16,19 while
increased pigment epithelium-derived factor has been
related to SCD retinopathy.15 Here we present data
demonstrating that the profile of circulating angiogenic
factors is significantly altered in SCD individuals, with
corresponding effects on plasma angiogenic activity.  
Plasma from a cohort of SCA (HbSS) patients contained
higher concentrations of a number of pro-angiogenic fac-
tors (Ang1, bFGF, VEGF, VEGF-D and PlGF), compared
with concentrations in control plasma. Ang1 induces vas-
cular remodeling and enlargement via highly organized
angiogenesis and tightening of EC junctions.33 bFGF and
VEGF play synergistic roles in angiogenesis,34 in which
bFGF (released from the extracellular matrix during
wound healing) stimulates multiple cell types,35 while
VEGF is EC-selective and has potent vasopermeability
activity, playing a primary role in angiogenesis by induc-
ing EC proliferation, sprouting and tube formation.36,37
VEGF-D is essential for hypoxia-driven vascular develop-
ment,37 and PlGF enhances VEGF-stimulated angiogenesis
under pathological conditions.38 Anti-angiogenic mole-
cules, such as the matrix-derived peptide, endostatin, and
the matrix-binding protein, TSP-2, are important for tissue
repair and regeneration, since they prune superfluous ves-
sels forming a stable, well-perfused vascular network;39
however, neither endostatin nor TSP-2 concentrations
were altered in SCA patients not on hydroxyurea. Vaso-
occlusive events in SCD result in the occurrence of tissue
ischemia, generating hypoxic conditions, EC activation,
inflammatory events and the up-regulation of endothelial
HIF-1,40 known to induce the transcription of genes that
drive angiogenesis, including VEGF.41 Thus, it would seem
likely that such events participate in the observed up-reg-
ulation of pro-angiogenic factors.
In addition to the increased concentrations of pro-angio-
genic factors observed in the circulation of SCA (HbSS)
individuals, these plasma samples had potent pro-angio-
genic activity, significantly accelerating the formation of
capillary-like structures from EC on Matrigel and increas-
ing the proliferation and invasion of these cells in vitro. The
concentrations of a number of pro-angiogenic factors cor-
related significantly with the ability of the respective plas-
ma samples to induce EC capillary-formation and invasive
activity. As such, the elevated production of circulating
pro-angiogenic factors in SCA appears to have physiolog-
ically relevant effects on major steps of EC-dependent
angiogenesis. While multiple angiogenic factors may be
involved in these effects, Ang1, VEGF and VEGF-D,
whose concentrations correlated highly with EC invasion
and vessel assembly, seem to contribute significantly to
this activity, in keeping with the hypoxic nature of SCA.
Moreover, compared to control mice, SCD mice demon-
strated a significantly higher vascularization of Matrigel
plugs over a 7-day period, confirming that this highly pro-
angiogenic environment may stimulate neovasculariza-
tion in vivo.
Although HbSC disease is associated with a clinically
milder phenotype relative to SCA, the incidence of periph-
eral retinopathy is much higher in the former; hence
HbSC patients from our cohort were divided into those
without peripheral retinopathy (SC) and those with
peripheral retinopathy (SCR).11 We were careful to exclude
any patients with peripheral retinopathy from the SCA
(HbSS) group, in an attempt to identify specific differences
in angiogenic profile between the HbSS and HbSC groups.
Interestingly, HbSC individuals had a very different plas-
ma angiogenic profile to that of HbSS individuals. Only
PlGF levels were raised in HbSC plasma, together with a
slight increment in VEGF-D. In contrast, plasma levels of
the anti-angiogenic molecules, endostatin and TSP-2, were
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Figure 6. In vivo angiogenesis is augmented in SCD chimeric mice and inhibited by hydroxyurea. A Matrigel plug neovascularization assay was
employed to compare neovascularization in SCD chimeric (SS) and C57BL/6 mice and observe the effects of hydroxyurea on in vivo vessel for-
mation. The following were injected subcutaneously into C57BL/6 and SS mice; a mixture of Matrigel and heparin without vascular endothelial
growth factor (VEGF-, negative control); Matrigel, heparin and VEGF (VEGF +, positive control) or Matrigel, heparin, VEGF and 100 μM hydroxy -
urea (VEGF+HU). Matrigel plugs were left in place for 7 days. (A) Quantification of hemoglobin (Hb) in the homogenized Matrigel plugs using
Drabkin solution, results are expressed as Hb content in the Matrigel plug (mg/g) (mean±SEM; C57BL/6, n=5; SS, n=4-6). (B) Representative
photomicrographs of Matrigel plugs. Scale bars, 1 cm.* P<0.05 vs. C57BL6; #P<0.05 vs. VEGF+HU.
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significantly increased in HbSC disease in the absence of
retinopathy. In accordance with the lower concentrations
of pro-angiogenic factors in the circulation of HbSC
patients, plasma from these individuals did not significant-
ly alter EC proliferation and activated EC capillary forma-
tion and invasion to a lesser degree than retinopathic
HbSC plasma. Plasma from HbSC patients with peripheral
retinopathy was significantly more pro-angiogenic,
demonstrating elevated concentrations of Ang1, VEGF,
VEGF-D and PlGF, with no alterations in anti-angiogenic
molecule content. Remarkably, this pro-angiogenic plasma
induced similar alterations in EC invasion and capillary-
formation abilities to those observed for HbSS plasma.
Correlations between HbSC plasma factor content and
angiogenic activity were found only between plasma
VEGF-D content and EC capillary formation and prolifer-
ation in HbSC, implicating VEGF-D as a primordial factor
in HbSC neovascularization. 
Due to the large variability in the phenotype of SCA,
and the size of the group of patients, plasma angiogenic
activity was not correlated with any one clinical manifes-
tation of the disease, but it may be speculated that such
potent pro-angiogenic activity (potentially leading to
uncontrolled neovascularization) may contribute to some
clinical manifestations of the disease, including pulmonary
hypertension, moyamoya vasculopathy and even other
events such as nephropathy.42 Importantly, while a clear
difference between the angiogenic activities of retinopath-
ic HbSC plasma and non-retinopathic HbSC plasma was
observed, the angiogenic profile of retinopathic HbSC
plasma was very similar to that of plasma from the SCA
(HbSS) group of patients, none of whom demonstrated
retinopathy. As such, it remains unclear as to why the
highly pro-angiogenic environment of SCA (HbSS) rarely
results in retinopathy, while pro-angiogenic factors appear
to influence the incidence of peripheral retinopathy in
HbSC. It seems probable that additional factors may par-
ticipate in the development of peripheral retinopathy in
HbSC; for instance, hemoglobin concentrations, and
therefore blood viscosity, are higher in HbSC (see Table 1)
and it may be that this viscosity, coupled with the produc-
tion of angiogenic factors, incurs damage to the fragile
retina. It has also been suggested that, in SCA, peripheral
vessels are occluded much earlier on and more extensively,
preventing further retinal damage and the formation of
proliferative lesions;11 however, more studies are required
to provide support for these hypotheses.
We recently reported that hydroxyurea has anti-angio-
genic effects both in vitro and in vivo, inhibiting EC HIF-1α
gene expression, capillary-structure formation, prolifera-
tion and invasion in vitro, as well as preventing in vivo neo-
vascularization in C57BL/6 mice.27 Importantly, hydroxy -
urea therapy also appears to affect the circulating angio-
genic molecule profile in SCD. In SCA, hydroxyurea ther-
apy was associated with lowering of the raised levels of
Ang1, bFGF and VEGF and decreases in VEGF-D, PDGF-
AA and PDGF-BB. Accordingly, in a retinopathic HbSC
patient on hydroxyurea, pro-angiogenic factor concentra-
tions were not elevated when compared with concentra-
tions in control plasma. Furthermore, hydroxyurea therapy
was associated with significant increases in the produc-
tions of anti-angiogenic endostatin and TSP-2 in HbSS.
While longitudinal studies are required to confirm whether
hydroxyurea therapy has a direct effect on endothelial HIF-
1 expression, known to be up-regulated in SCD mice40, the
potent anti-angiogenic effects of hydroxyurea on EC,27
together with the reduction in the incidence of hypoxic
events in patients on hydroxyurea, may result in alterations
in the production and secretion of these angiogenic factors.
Concomitant inhibition of EC-angiogenic function was
observed in vitro in the presence of plasma from SCD
patients on hydroxyurea. Whether these alterations in EC-
angiogenic mechanisms were inhibited by alterations in
plasma angiogenic factor content or due to the presence of
the hydroxyurea compound or its metabolites in the plas-
ma (or a combination of these alterations) is not clear. The
anti-angiogenic effects of hydroxyurea, including suppres-
sion of endothelial HIF-1α gene expression,27 and elevation
of endostatin (which prevents retinal neovascularization
and interferes in leg ulcer healing43,44) may have important
consequences in SCD. While hydroxyurea therapy could
be beneficial for clinical manifestations in which unregulat-
ed neovascularization participates, mechanisms for which
angiogenesis may be important, such as wound healing
and vascularization of infarcted tissues, may be hindered
by this molecule. Although simultaneous improvements in
vaso-occlusive mechanisms may outweigh the effects of
hydroxyurea on angiogenic processes, there is some evi-
dence to suggest that hydroxyurea therapy may compli-
cate leg ulcer healing in SCD and myeloproliferative dis-
eases45,46 and further studies to explore the anti-angiogenic
effects of hydroxyurea may be warranted. 
In summary, the circulating vascular milieu encountered
in SCA and retinopathic HbSC individuals is highly pro-
angiogenic and capable of stimulating EC-mediated angio-
genic mechanisms, in association with alterations in SCD
neovascularization. While this pro-angiogenic state
appears to participate in retinopathy in HbSC disease, the
exact role that this unbalanced angiogenesis and unregu-
lated neovascularization plays in the clinical manifesta-
tions of SCD needs to be clarified. Furthermore, the bene-
fits and drawbacks of the apparent anti-angiogenic effects
of hydroxyurea therapy in SCD require attention, as does
the potential for the use of hydroxyurea as a therapeutic
approach for HbSC retinopathy. 
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